Abstract
Tagrisso is the third generation irreversible EGFR tyrosine kinase inhitor and it was recently approved by European Commission at dosage 80mg in one tablet once a day for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with positive EGFR mutation T790M, which is resistent to the first generation EGFR tyrosine kinase inbitors.